Tetravalent
Target indications: hand, foot, and mouth disease · encephalitis
Pipeline
Enterovirus vaccine pipeline
Efficient multivalent VLP vaccines against enterovirus do not exist. Velocin brings one recombinant VLP platform across enterovirus groups: multivalent, no live or weakened virus, scalable.
Hexavalent
Target indications: myocarditis · meningitis · type 1 diabetes
Bivalent
Target indications: severe respiratory illness · flaccid myelitis
Trivalent
Target indications: flaccid myelitis · paralysis
Development path
One lead candidate to a first-in-human study
All four candidates go through screening. One lead candidate, selected during preclinical development, advances through a first-in-human Phase I study.
Platform development
Years 0–1.5 · screening and process development
- Feasibility screen: 15 prioritized enteroviruses
- Program candidates nominated
- CDMO selected
- PCT application filed
Preclinical
Years 1.5–4
- Lead candidate selection
- GMP-representative batch and stability studies
- Safety and toxicology
- Immunogenicity and efficacy
- Regulatory scientific advice → CTA/IND submission
Clinical Phase I
Years 4–6
- GMP manufacturing
- First-in-human Phase I study
- Interim Phase I readout
- Final Phase I readout
Evidence
Technical risk retired, stage by stage
15.5 person-years of wet-lab work have already proven design, manufacturing and protection of the enterovirus vaccine, backed by 17 published articles. 8 / 8 key risks addressed.
State-of-the-art design of the efficient antigen
2 person-years · proprietary antigen successfully produced in vitro.
Manufacturing improved up to 100x
8 person-years · multivalent batches, high yield and purity achieved.
Demonstrated immunogenicity in vivo
5.5 person-years · dosing, delivery, challenge model in animals proven.
Still ahead
GMP scale-up, toxicology, Phase I.
Remaining risk in the enterovirus vaccine development is related to the clinical trial results rather than technical feasibility of the vaccine.
Beyond enteroviruses
One platform, several markets
Enter
Enter through pediatric enteroviruses, where no broadly protective vaccine is licensed in Western markets.
Expand
Expand the same platform into established respiratory vaccine markets, differentiating on effectiveness, speed, and egg-free supply.
Extend
Extend into pandemic preparedness through largely non-dilutive government funding that de-risks the broader platform.
Intellectual property
Filings across the VLP platform
Current and planned filings span VLP composition, manufacturing, and downstream applications. The first application was filed in Finland, and a PCT filing is underway.
Antigen design
Proprietary decoy-region deletions are designed to improve production yield and candidate safety, with rapid adaptation to emerging and evolving strains.
Manufacturing and formulation
Proprietary production methods support flexible scale-up. Combination vaccine formulations cover composition and delivery approaches.
Beyond vaccines
Proprietary immunoassays and analytical methods, and coverage extending to immunotherapeutics and diagnostics, create multiple paths from one platform.
Partner on the pipeline
Velocin plans to out-license vaccine candidates to pharmaceutical partners after Phase I, starting from enterovirus.